Your browser doesn't support javascript.
loading
DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets.
Raies, Arwa; Tulodziecka, Ewa; Stainer, James; Middleton, Lawrence; Dhindsa, Ryan S; Hill, Pamela; Engkvist, Ola; Harper, Andrew R; Petrovski, Slavé; Vitsios, Dimitrios.
Affiliation
  • Raies A; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Tulodziecka E; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Stainer J; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Middleton L; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Dhindsa RS; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.
  • Hill P; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, USA.
  • Engkvist O; Emerging Innovations, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.
  • Harper AR; Molecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
  • Petrovski S; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Vitsios D; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Commun Biol ; 5(1): 1291, 2022 11 24.
Article in En | MEDLINE | ID: mdl-36434048
The druggability of targets is a crucial consideration in drug target selection. Here, we adopt a stochastic semi-supervised ML framework to develop DrugnomeAI, which estimates the druggability likelihood for every protein-coding gene in the human exome. DrugnomeAI integrates gene-level properties from 15 sources resulting in 324 features. The tool generates exome-wide predictions based on labelled sets of known drug targets (median AUC: 0.97), highlighting features from protein-protein interaction networks as top predictors. DrugnomeAI provides generic as well as specialised models stratified by disease type or drug therapeutic modality. The top-ranking DrugnomeAI genes were significantly enriched for genes previously selected for clinical development programs (p value < 1 × 10-308) and for genes achieving genome-wide significance in phenome-wide association studies of 450 K UK Biobank exomes for binary (p value = 1.7 × 10-5) and quantitative traits (p value = 1.6 × 10-7). We accompany our method with a web application ( http://drugnomeai.public.cgr.astrazeneca.com ) to visualise the druggability predictions and the key features that define gene druggability, per disease type and modality.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Software / Machine Learning Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Commun Biol Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Main subject: Software / Machine Learning Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Commun Biol Year: 2022 Type: Article